BIOMAT Database Logo BIOMAT Database Logo

[ACF combination consisting of adriamycin, cyclophosphamide and oral futraful for recurrent advanced breast cancer (author's transl)]. 1981

S Murosaki, and J Inagaki, and N Horikoshi, and K Esaki, and K Inoue, and E Nagura, and H Ueoka, and Y Takano, and T Kobayashi, and K Okabe, and M Ogawa

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Murosaki, and J Inagaki, and N Horikoshi, and K Esaki, and K Inoue, and E Nagura, and H Ueoka, and Y Takano, and T Kobayashi, and K Okabe, and M Ogawa
[Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer].
October 1994, Gan to kagaku ryoho. Cancer & chemotherapy,
S Murosaki, and J Inagaki, and N Horikoshi, and K Esaki, and K Inoue, and E Nagura, and H Ueoka, and Y Takano, and T Kobayashi, and K Okabe, and M Ogawa
Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.
July 1975, Cancer,
S Murosaki, and J Inagaki, and N Horikoshi, and K Esaki, and K Inoue, and E Nagura, and H Ueoka, and Y Takano, and T Kobayashi, and K Okabe, and M Ogawa
[A study on the efficacy of combination chemoendocrine therapy consisting of cyclophosphamide, adriamycin, UFT, and tamoxifen for advanced or recurrent breast cancer].
July 1999, Gan to kagaku ryoho. Cancer & chemotherapy,
S Murosaki, and J Inagaki, and N Horikoshi, and K Esaki, and K Inoue, and E Nagura, and H Ueoka, and Y Takano, and T Kobayashi, and K Okabe, and M Ogawa
[A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer].
September 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
S Murosaki, and J Inagaki, and N Horikoshi, and K Esaki, and K Inoue, and E Nagura, and H Ueoka, and Y Takano, and T Kobayashi, and K Okabe, and M Ogawa
A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer.
January 1984, Cancer chemotherapy and pharmacology,
S Murosaki, and J Inagaki, and N Horikoshi, and K Esaki, and K Inoue, and E Nagura, and H Ueoka, and Y Takano, and T Kobayashi, and K Okabe, and M Ogawa
[Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
May 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
S Murosaki, and J Inagaki, and N Horikoshi, and K Esaki, and K Inoue, and E Nagura, and H Ueoka, and Y Takano, and T Kobayashi, and K Okabe, and M Ogawa
Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide (VAC).
January 1979, Cancer,
S Murosaki, and J Inagaki, and N Horikoshi, and K Esaki, and K Inoue, and E Nagura, and H Ueoka, and Y Takano, and T Kobayashi, and K Okabe, and M Ogawa
[A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer].
March 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
S Murosaki, and J Inagaki, and N Horikoshi, and K Esaki, and K Inoue, and E Nagura, and H Ueoka, and Y Takano, and T Kobayashi, and K Okabe, and M Ogawa
Efficacy of postoperative adjuvant therapy for stage ilia breast cancer: Futraful vs futraful+tamoxifen for ER-positive patients and futraful vs futraful + adriamycin for ER-negative breast cancer.
January 1997, Breast cancer (Tokyo, Japan),
S Murosaki, and J Inagaki, and N Horikoshi, and K Esaki, and K Inoue, and E Nagura, and H Ueoka, and Y Takano, and T Kobayashi, and K Okabe, and M Ogawa
[A combined immuno-chemotherapy with futraful and picibanil for advanced cancer (author's transl)].
September 1977, Nihon Gan Chiryo Gakkai shi,
Copied contents to your clipboard!